In a nutshell This article looked at the effectiveness and safety of anlotinib (AL3818) for non-responsive advanced non-small cell lung cancer (NSCLC). The authors found that anlotinib was an effective third-line or later line therapy for patients with unresponsive advanced NSCLC. Some background NSCLC accounts for 85% of lung cancers found...
Read More
In a nutshell This study aimed to investigate the combination of dasatinib (Sprycel) and blinatumomab (Blincyto) as a first-line therapy in patients with Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL). This study concluded that this treatment combination led to better response and survival in these...
Read More
In a nutshell This study was carried out to assess the long-term outcomes of men diagnosed with prostate cancer (PC) undergoing active surveillance (AS) and factors that predicted the risk of their cancer spreading (metastasizing). The authors found that AS is a safe and viable option for men with low-risk and carefully-selected intermediate-risk...
Read More
In a nutshell The study compared outcomes of lorlatinib (Lorbrena) with crizotinib (Xalkori) in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) with ALK mutations (genetic abnormalities). The main finding was that patients receiving lorlatinib had longer progression-free survival (PFS) and a higher response in the...
Read More
In a nutshell This study was carried out to assess the long-term safety and effectiveness of magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) in patients with localized prostate cancer. The authors found that TULSA was safe and effective, with preserved quality of life. Some background Prostate cancer is one...
Read More
In a nutshell This study aimed to compare the effectiveness of acalabrutinib (Calquence) alone and in combination with obinutuzumab (Gazyva) to standard treatments for patients with chronic lymphocytic leukemia (CLL). This study concluded that acalabrutinib showed high effectiveness...
Read More
In a nutshell This study aimed to investigate three different chemotherapy-free treatment regimens for patients with chronic lymphocytic leukemia. This study concluded that acalabrutinib (Calquence) plus obinutuzumab (Gazyva) improved survival without cancer worsening for these patients. Some background Chemotherapy-free...
Read More
In a nutshell This study examined the effectiveness of complete surgical removal of aggressive non-Hodgkin lymphoma (NHL). The authors found that in young patients with diffuse large B-cell lymphoma (DLBCL) may benefit from complete surgical removal of the tumor before immunochemotherapy (ICT). Some background Lymphoma is a cancer that...
Read More
In a nutshell This trial was carried out to assess the effectiveness of azacitidine (Vidaza) in combination with venetoclax (Venclexta) for the treatment of untreated acute myeloid leukemia (AML) in older adults. The authors concluded that this combination prolonged survival and induced more remissions in these patients. Some...
Read More
In a nutshell This study compared surgery and radiotherapy for treating localized prostate cancer. They found no significant difference in survival between the two treatments. Some background Localized prostate cancer (cancer which has not spread beyond the prostate gland) can be treated with either surgery, radiotherapy, or monitoring without...
Read More
In a nutshell This study examined the effectiveness and safety of the drug combination pertuzumab (Perjeta) and trastuzumab (Herceptin) as a treatment for breast cancer (BC) with positive HER2 (human epidermal growth factor receptor 2) before surgery to remove the tumor in a real-world setting. The data showed that this...
Read More
In a nutshell The study evaluated outcomes of sorafenib (Nexavar) maintenance therapy after allogeneic hematopoietic stem cell transplantation (alloHSCT) in patients with acute myeloid leukemia (AML) carrying FLT3-ITD mutation (abnormal gene). The authors found that this therapy was effective and tolerable after aHSCT in such patients. Some...
Read More
